Cresset Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.23M | Buy |
65,104
+923
| +1% | +$122K | 0.03% | 325 |
|
|
2026
Q1 | $8.94M | Buy |
64,181
+2,422
| +4% | +$339K | 0.04% | 276 |
|
|
2025
Q4 | $7.58M | Buy |
61,759
+4,099
| +7% | +$498K | 0.03% | 296 |
|
|
2025
Q3 | $6.4M | Buy |
57,660
+3,836
| +7% | +$436K | 0.03% | 310 |
|
|
2025
Q2 | $5.97M | Sell |
53,824
-7,912
| -13% | -$842K | 0.03% | 306 |
|
|
2025
Q1 | $6.92M | Sell |
61,736
-15,218
| -20% | -$1.57M | 0.03% | 295 |
|
|
2024
Q4 | $7.11M | Sell |
76,954
-74,671
| -49% | -$6.72M | 0.03% | 289 |
|
|
2024
Q3 | $12.7M | Buy |
151,625
+24,013
| +19% | +$1.83M | 0.05% | 252 |
|
|
2024
Q2 | $8.76M | Buy |
127,612
+31,695
| +33% | +$2.12M | 0.04% | 311 |
|
|
2024
Q1 | $7.03M | Buy |
95,917
+916
| +1% | +$70.4K | 0.03% | 322 |
|
|
2023
Q4 | $7.7M | Buy |
95,001
+4,898
| +5% | +$381K | 0.05% | 254 |
|
|
2023
Q3 | $6.75M | Sell |
90,103
-7,038
| -7% | -$541K | 0.03% | 273 |
|
|
2023
Q2 | $7.49M | Buy |
97,141
+78,956
| +434% | +$6.3M | 0.01% | 323 |
|
|
2023
Q1 | $1.51M | Sell |
18,185
-3,556
| -16% | -$295K | 0.03% | 266 |
|
|
2022
Q4 | $1.47M | Sell |
21,741
-923
| -4% | -$73.1K | 0.02% | 241 |
|
|
2022
Q3 | $1.4M | Sell |
22,664
-1,904
| -8% | -$120K | 0.02% | 277 |
|
|
2022
Q2 | $1.51M | Sell |
24,568
-507
| -2% | -$31.4K | 0.02% | 275 |
|
|
2022
Q1 | $1.49M | Sell |
25,075
-15,414
| -38% | -$985K | 0.02% | 313 |
|
|
2021
Q4 | $2.94M | Sell |
40,489
-95
| -0.2% | -$6.54K | 0.03% | 231 |
|
|
2021
Q3 | $2.83M | Buy |
40,584
+7,094
| +21% | +$498K | 0.04% | 175 |
|
|
2021
Q2 | $2.31M | Buy |
33,490
+10,347
| +45% | +$691K | 0.03% | 183 |
|
|
2021
Q1 | $1.5M | Buy |
23,143
+2,679
| +13% | +$173K | 0.02% | 217 |
|
|
2020
Q4 | $1.19M | Sell |
20,464
-4,652
| -19% | -$281K | 0.02% | 214 |
|
|
2020
Q3 | $1.59M | Sell |
25,116
-1,823
| -7% | -$126K | 0.03% | 182 |
|
|
2020
Q2 | $2.06M | Buy |
26,939
+8,035
| +43% | +$616K | 0.05% | 145 |
|
|
2020
Q1 | $1.41M | Buy |
18,904
+7,184
| +61% | +$496K | 0.04% | 146 |
|
|
2019
Q4 | $762K | Buy |
11,720
+3,429
| +41% | +$223K | 0.02% | 243 |
|
|
2019
Q3 | $525K | Buy |
8,291
+1,283
| +18% | +$83.9K | 0.02% | 264 |
|
|
2019
Q2 | $473K | Sell |
7,008
-3,614
| -34% | -$238K | 0.01% | 255 |
|
|
2019
Q1 | $691K | Sell |
10,622
-611
| -5% | -$40.6K | 0.03% | 147 |
|
|
2018
Q4 | $703K | Buy |
+11,233
| New | +$785K | 0.04% | 98 |
|
Other funds holding GILD
Cresset Asset Management's GILD Position: Q2 2026 in Review
Cresset Asset Management increased its Gilead Sciences (GILD) stake by 1.4% in Q2 2026, buying an estimated $122K and bringing the position to 65,104 shares worth $8.23M. The position accounts for 0.03% of the portfolio, ranked #325.
Cresset Asset Management first reported a position in GILD in Q4 2018 and has held it in 31 quarters since. The position peaked at $12.7M in Q3 2024. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Cresset Asset Management held 65,104 shares of Gilead Sciences worth $8.23M as of Q2 2026.
- Cresset Asset Management bought 923 Gilead Sciences shares in Q2 2026, an estimated $122K.
- Gilead Sciences made up 0.03% of Cresset Asset Management's portfolio in Q2 2026, its #325 holding.
- Cresset Asset Management first reported a position in Gilead Sciences in Q4 2018 and has held it in 31 quarters since.
- Cresset Asset Management's Gilead Sciences position peaked at $12.7M in Q3 2024.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.